Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.49 |
| ▸ | FLT3 | P36888 | 2/20 | 0.46 |
| ▸ | BLK | P51451 | 2/20 | 0.46 |
| ▸ | JAK3 | P52333 | 5/20 | 0.45 |
| ▸ | JAK2 | O60674 | 3/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.45 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.44 |
| ▸ | PIP4K2A | P48426 | 4/20 | 0.44 |
| ▸ | PIP4K2B | P78356 | 4/20 | 0.44 |
| ▸ | SRC | P12931 | 2/20 | 0.44 |
| ▸ | BTK | Q06187 | 3/20 | 0.42 |
| ▸ | ITK | Q08881 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14706384 | 0.91 | FGFR2 (0.42) | EGFRFLT3BLKJAK3JAK2 | |
| SCHEMBL14706375 | 0.89 | FGFR2 (0.45) | EGFRFLT3BLKJAK3JAK2 | |
| SCHEMBL14693451 | 0.85 | SRC (0.53) | EGFRJAK3SRCBTKITK | |
| SCHEMBL14693455 | 0.85 | SRC (0.53) | EGFRJAK3SRCBTKITK | |
| SCHEMBL14693423 | 0.83 | BTK (0.53) | EGFRFGFR2SRCBTKITK | |
| SCHEMBL14693422 | 0.83 | BTK (0.53) | EGFRFGFR2SRCBTKITK | |
| SCHEMBL14706388 | 0.81 | JAK3 (0.47) | EGFRFLT3BLKJAK3JAK2 | |
| SCHEMBL14693470 | 0.77 | BTK (0.46) | EGFRFGFR2BTKITK | |
| SCHEMBL14693472 | 0.77 | BTK (0.46) | EGFRFGFR2BTKITK | |
| SCHEMBL14693495 | 0.77 | SRC (0.49) | EGFRSRCBTKITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9546172-B2 | Pyrazolo[3,4-d]pyrimidine and pyrazolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2017-01-17 | — | — | US | disclosed |
| US-9546172-B2 | Pyrazolo[3,4-d]pyrimidine and pyrazolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2017-01-17 | — | — | US | disclosed |
| US-9273051-B2 | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273051-B2 | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2016-03-01 | — | — | US | disclosed |
| US-20130172314-A1 | PYRAZOLO[3,4-d]PYRIMIDINE AND PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130172314-A1 | PYRAZOLO[3,4-d]PYRIMIDINE AND PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-8377946-B1 | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377946-B1 | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172314-A1 | PYRAZOLO[3,4-d]PYRIMIDINE AND PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | BTK, LCK, LYN | EGFR 1715/4885FLT3 58/4885BLK 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.